Program
PF-08653945
A development code.
In Pfizer's pipeline, Amylin analog (with dual amylin and calcitonin receptor activity)
. Its studies are mostly in Obesity, led by Pfizer.
Furthest: phase 2, since May 4, 20262 company-led studies, 2 open or runningNext primary completion: Jan 13, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 22 open or running | phase 2since May 4, 2026 | May 4, 2026 | Jan 13, 2027phase 1 · NCT07725809 |
- Named in Pfizer’s own pipeline as
PF-08653945
, phase 2, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 4, 2026First study: phase 2 study in OverweightFirst studyNCT07575932 · 940 enrolled · United States, Canada
- Jul 21, 2026Phase 1 study in OverweightNCT07725809 · 57 enrolled · Belgium
Ahead
- Jan 13, 2027Primary completion: phase 1 study in OverweightNCT07725809
- Aug 4, 2027Primary completion: phase 2 study in OverweightNCT07575932
TargetBeta
“Amylin analog (with dual amylin and calcitonin receptor activity)”the company's pipeline, read by Claude · source
Other programs on CALCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cagrilintide | Novo Nordisk | phase 3 | 50 |
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| petrelintiderule | Zealand Pharma | phase 3 | 11 |
| ABBV-295 | AbbVie | phase 2 | 5 |
| GUB014295 | AbbVie | phase 1 | 1 |
| CagriSema A | Novo Nordisk | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07725809Overweight · Belgium | 1 | Active, not recruiting | Jan 13, 2027 | 57 |
| NCT07575932Overweight · United States, Canada | 2 | Active, not recruiting | Aug 4, 2027 | 940 |
How it is read
Names in the registry
- “PF-08653945”, 2 entries
Codes read as this program: PF08653945.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.